Invivyd Inc (IVVD)

$0.51 +0.04 (8.21%)
Market Cap 61.18M
Revenue (ttm) 25.38M
Net Income (ttm) -169.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 5.24
Profit Margin -669.54%
Debt to Equity Ratio 0.00
Volume 1,633,100
Avg Vol 6,009,758
Day's Range N/A - N/A
Shares Out 119.96M
Stochastic %K 42%
Beta 0.41
Analysts Strong Sell
Price Target $7.20

Latest News on IVVD

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 26, 2025, 4:15 PM EDT - 25 days ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 20, 2025, 8:01 AM EDT - 4 weeks ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Mar 5, 2025, 7:05 AM EST - 6 weeks ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 9:20 AM EST - 7 weeks ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 2 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 10, 2025, 7:00 AM EST - 2 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 5, 2025, 9:30 AM EST - 2 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 4, 2025, 3:55 PM EST - 2 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Feb 3, 2025, 6:55 AM EST - 2 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 27, 2025, 7:01 AM EST - 3 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Jan 10, 2025, 7:01 AM EST - 3 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:15 PM EST - 5 months ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:05 AM EST - 5 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Nov 14, 2024, 7:01 AM EST - 5 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Nov 12, 2024, 8:30 AM EST - 5 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 8:01 AM EST - 5 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Nov 6, 2024, 7:01 AM EST - 5 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Oct 29, 2024, 7:03 AM EDT - 6 months ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Oct 29, 2024, 7:01 AM EDT - 6 months ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Oct 16, 2024, 7:01 AM EDT - 6 months ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Oct 1, 2024, 7:01 AM EDT - 7 months ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Sep 23, 2024, 7:01 AM EDT - 7 months ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Sep 12, 2024, 7:01 AM EDT - 7 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd to Participate in Upcoming Investor Conferences

Sep 5, 2024, 7:01 AM EDT - 8 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Sep 4, 2024, 7:01 AM EDT - 8 months ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

Sep 3, 2024, 7:01 AM EDT - 8 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Aug 27, 2024, 7:01 AM EDT - 8 months ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 2:39 PM EDT - 8 months ago

Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 14, 2024, 8:01 AM EDT - 8 months ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

Aug 12, 2024, 4:01 PM EDT - 8 months ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jul 1, 2024, 7:01 AM EDT - 10 months ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Jun 14, 2024, 7:01 AM EDT - 11 months ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Invivyd to Participate at the Jefferies Global Healthcare Conference

Jun 3, 2024, 4:01 PM EDT - 11 months ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial

May 31, 2024, 7:05 AM EDT - 11 months ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

May 31, 2024, 7:00 AM EDT - 11 months ago

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

May 29, 2024, 7:00 AM EDT - 11 months ago

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Invivyd Elects Two New Independent Members to its Board of Directors

May 22, 2024, 7:00 AM EDT - 11 months ago

Invivyd Elects Two New Independent Members to its Board of Directors

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 4:01 PM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:37 PM EDT - 1 year ago

Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

May 7, 2024, 7:30 AM EDT - 1 year ago

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

May 2, 2024, 5:13 PM EDT - 1 year ago

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Apr 15, 2024, 7:30 AM EDT - 1 year ago

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Invivyd Announces CEO Transition

Apr 12, 2024, 7:30 AM EDT - 1 year ago

Invivyd Announces CEO Transition

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Apr 4, 2024, 4:01 PM EDT - 1 year ago

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Mar 22, 2024, 3:28 PM EDT - 1 year ago

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Mar 22, 2024, 3:04 PM EDT - 1 year ago

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 4:02 PM EST - 1 year ago

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference